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Abstract
Background: Hypoxemia is common in pulmonary hypertension (PH) and may be partly related
to ventilation/perfusion mismatch, low diffusion capacity, low cardiac output, and/or right-to-left
(RL) shunting.
Methods: To determine whether true RL shunting causing hypoxemia is caused by intracardiac
shunting, as classically considered, a retrospective single center study was conducted in consecutive
patients with precapillary PH, with hypoxemia at rest (PaO2 < 10 kPa), shunt fraction (Qs/Qt)
greater than 5%, elevated alveolar-arterial difference of PO2 (AaPO2), and with transthoracic
contrast echocardiography performed within 3 months.
Results: Among 263 patients with precapillary PH, 34 patients were included: pulmonary arterial
hypertension, 21%; PH associated with lung disease, 47% (chronic obstructive pulmonary disease,
23%; interstitial lung disease, 9%; other, 15%); chronic thromboembolic PH, 26%; miscellaneous
causes, 6%. Mean pulmonary artery pressure, cardiac index, and pulmonary vascular resistance
were 45.8 ± 10.8 mmHg, 2.2 ± 0.6 L/min/m2, and 469 ± 275 dyn.s.cm-5, respectively. PaO2 in room
air was 6.8 ± 1.3 kPa. Qs/Qt was 10.2 ± 4.2%. AaPO2 under 100% oxygen was 32.5 ± 12.4 kPa.
Positive contrast was present at transthoracic contrast echocardiography in 6/34 (18%) of patients,
including only 4/34 (12%) with intracardiac RL shunting. Qs/Qt did not correlate with
hemodynamic parameters. Patients' characteristics did not differ according to the result of contrast
echocardiography.
Conclusion: When present in patients with precapillary PH, RL shunting is usually not related to
reopening of patent foramen ovale, whatever the etiology of PH.
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Background
Pulmonary hypertension (PH) is characterized by
increased pulmonary artery pressure, ultimately leading
to right heart failure and death. PH encompasses various
etiologic groups, including pulmonary arterial hyperten-
sion (PAH) – group 1, PH related to left heart disease –
group 2, PH associated with lung diseases and/or hypox-
emia – group 3, PH due to chronic thrombotic and/or
embolic disease – group 4, and miscellaneous disorders,
including sarcoidosis and Langerhans cell histiocytosis –
group 5 [1].
PAH per se affects small pulmonary arteries, with vascular
remodelling leading to progressive increase in pulmonary
vascular resistance (PVR) [2]. It may be idiopathic, famil-
ial, or associated with a variety of conditions merged
under the common denomination of PAH due to similar-
ities in histopathological features, natural history, and
treatment [1]. Precapillary PH is defined by PH with pul-
monary artery wedge pressure (PAWP) no greater than 15
mmHg and PVR greater than 240 dyn.s.cm-5 [1]. In addi-
tion to PAH, precapillary PH may be encountered as a
result of various disorders (etiologic groups 3, 4, and 5),
and may also be characterized by remodelling of the small
pulmonary arteries although less data are available than
in PAH.
Mild to moderate hypoxemia is common in precapillary
PH, and most often coexists with respiratory alkalosis.
Hence, the mean PaO2 was 9.5 ± 2 kPa in the National
Institutes of Health PAH registry [3] and 9.2 ± 1.9 kPa in
a more recent study [4]. However, hypoxemia in PH may
sometimes be severe and contribute to exercise intoler-
ance. Desaturation of 10% or more during 6-minute walk
test is associated with a relative mortality risk of 2.9 in
PAH [5]. Desaturation may occur overnight in as many as
60% of patients with PAH [6].
Hypoxemia in precapillary PH may possibly be related to
ventilation/perfusion mismatch [7,8], low diffusion
capacity, low mixed venous PO2 due to decreased cardiac
output [9], and/or true right-to-left (RL) shunting, which
is classically considered to arise from the reopening of pat-
ent foramen ovale [3,10,11]. In clinical practice guidelines
for the diagnostic process of PAH, transthoracic contrast
echocardiography is recommended to look for evidence
of intracardiac shunting [11]. However, little evidence is
available in the medical literature regarding this issue.
Here, we studied consecutive patients with precapillary
PH, hypoxemia, and true RL shunting, in whom transtho-
racic contrast echocardiography was available, to deter-
mine whether true RL shunting causing hypoxemia is due
to intracardiac shunting and especially patent foramen
ovale.
Methods
A computer-aided search was conducted to identify all
adult patients evaluated for precapillary PH at our institu-
tion between January 2001 and March 2007. Patients with
RL shunting and available transthoracic contrast echocar-
diography were then selected using the computerized
database of the department of pulmonary function tests
and manual review of the medical records, respectively.
The study was approved by the Institutional Review Board
of the Société de Pneumologie de Langue Française. Informed
consent was obtained.
Inclusion criteria for this study included: (1) precapillary
PH as defined by mean pulmonary arterial pressure
(mPAP) greater than 25 mmHg at rest, with PAWP 15
mmHg or less, and PVR greater than 240 dyn.s.cm-5 at
right heart catheterization; [11] (2) hypoxemia defined by
PaO2 at rest less than 10 kPa; (3) RL shunting as defined
by shunt fraction (Qs/Qt) greater than 5%; (4) elevated
AaPO2 under 100% O2; and (5) transthoracic contrast
echocardiography performed within 3 months.
Causes of PH were classified according to the 2003 Venice
classification [1]. Patients with PH associated with con-
genital systemic-to-pulmonary shunts and those with a
known comorbidity potentially associated with a RL
shunt (e.g. hemorrhagic hereditary telangiectasia) were
excluded.
Shunt ratio (Qs/Qt) was calculated with the formula (Cc -
Ca)/(Cc - Cv) while breathing 100% oxygen [12]. Qs and
Qt corresponded to the shunt output and to total blood
flow through the lungs, respectively. Ca and Cv corre-
sponded to the oxygen contents of arterial and venous
blood, respectively. Cc was the oxygen contents of end-
capillary blood (with capillary PO2 estimated as similar to
alveolar PO2). In 10 patients in whom Cc was not availa-
ble, Qs/Qt was estimated with the formula (PAO2 - PaO2
mmHg)/(PAO2 - PaO2 mmHg + 1670) under 100% oxy-
gen [13]; estimation of Qs/Qt was validated in the
remaining 24 patients by comparison of Qs/Qt and esti-
mated Qs/Qt using Bland-Altman method; the bias value
was -0.1% ± 0.67 (95% confidence interval, -1.46 – 1.16).
Pulmonary function tests were performed according to
the European Respiratory Society guidelines [14]. AaPO2
while breathing 100% O2 was performed as described
elsewhere [15]; briefly, PaO2 was measured while the
patient had been breathing 100% O2 for at least 10–15
minutes, with a deep inspiration every minute and imme-
diately before drawing blood. Blood gas measurement
was performed immediately after blood drawing, in the
same room, with particular attention to eliminate air bub-
bles in the syringes. The actual PIO2 was measured to esti-
mate PAO2, with PAO2 (kPa) = PIO2 - 6.27 - (PaCO2/0.8),BMC Cardiovascular Disorders 2009, 9:15 http://www.biomedcentral.com/1471-2261/9/15
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and AaPO2 = PAO2 - PaO2. Thresholds of AaPO2 (18.6 kPa
in supine position, and 24.5 kPa in upright position)
determined previously [15] have excellent specificity
(98%), positive predictive value (97%), and positive like-
lihood ratio (21.8) for the diagnosis of RL shunting higher
than physiological shunting (5%).
Transthoracic contrast echocardiography (second har-
monic imaging) was performed by injecting 10 ml of agi-
tated isotonic saline solution mixed with 0.5 ml of room
air into a humeral vein while simultaneously imaging the
atria from the apical 4-chamber view with 2-D echocardi-
ography for at least 12 cardiac cycles. Contrast echocardi-
ography was performed both in supine and sitting
position, with Valsalva manoeuvre when negative. Intrac-
ardiac RL shunt was defined by appearance of any contrast
in the left atrium within 4 cardiac cycles, and intrapulmo-
nary shunt by a delayed contrast appearance (more than 5
cardiac cycles).
Right heart catheterization was performed using standard
procedures. A Swan-Ganz catheter was introduced into an
antecubital or femoral vein and guided under radioscopic
control into the pulmonary artery, until wedged position
was reached. Pressures were measured according to stand-
ard procedures. Cardiac output was calculated by cold
thermodilution (Edwards Lifesciences, Germany) from at
least 5 measurements. Arterial blood was drawn from the
Swan-Ganz catheter for the measurement of PO2 and the
mixed venous oxygen saturation (SvO2) (ABL820 Radi-
ometer, Copenhagen). Acute vasodilatator response was
defined by a reduction of mPAP ≥ 10 mmHg to reach an
absolute value of mPAP ≤ 40 mmHg, with an increased or
unchanged cardiac output [16,17].
Microsoft Excel 2003 and SPSS 12.1 were used for data
analysis. Data were presented as mean ± SD (range). Com-
parisons between groups were performed using the Mann-
Whitney U test, Kruskal Wallis test, and linear regression
analysis, when appropriate. Comparison of distribution
of causes were performed using Chi-square analysis. Two-
tailed p values < 0.05 were considered statistically signifi-
cant.
Results
Study population
Among 310 patients evaluated in our department for PH
during the study period, 263 had precapillary PH at right
heart catheterization; 34 of them fulfilling the other inclu-
sion criteria were included (figure 1). The clinical charac-
teristics of the patients are shown in table 1. The mean age
was 64 ± 15 years, and the male/female sex ratio was 1.3.
Etiologic groups of PH were as follows (table 2): 21% with
PAH (etiologic group 1); 47% with PH associated with
chronic parenchymal lung disease (group 3); 26% with
PH related to thromboembolic obstruction of distal pul-
monary arteries but not amenable to surgery (group 4);
6% with other causes (group 5). Distribution of etiologic
groups did not differ from the overall population of 263
patients evaluated for precapillary PH in our department.
Most patients had severe dyspnea, as the median New
York Heart Association (NYHA) functional class was III,
and 76% of patients had functional class III–IV. Accord-
ingly, the mean distance at 6-minute walk test was 271 ±
Table 1: Clinical and functional characteristics at the time of 
diagnosis of pulmonary hypertension.
Clinical and functional parameters Mean ± SD (range)
Age, yr 64.0 ± 15 (25–82)
Sex (M/F) 19/15
Ex- or active smokers, % 50
Dyspnea NYHA class III–IV, % 76
6-min-walk distance, m 271 ± 116 (32–465)
TLC, % predicted 89 ± 16 (51–121)
FEV1, % predicted 76 ± 20 (33–117)
FEV1/FVC, % 65 ± 11 (36–88)
DLco, % predicted 49 ± 30 (12–113)
DLco/VA, % predicted 51 ± 28 (11–113)
PaO2, kPa 6.8 ± 1.3 (4.5–10.0)
FEV1, forced expiratory volume in one second; TLC, total lung 
capacity; DLco, single-breath diffusing capacity of the lung for carbon 
monoxide; VA, alveolar volume; NYHA, New York Heart 
Association.
Data expressed are mean ± SD (range) for quantitative values.
Flowchart summarizing the selection and inclusion process Figure 1
Flowchart summarizing the selection and inclusion 
process. PH, pulmonary hypertension; TTCE, transthoracic 
contrast echocardiography.BMC Cardiovascular Disorders 2009, 9:15 http://www.biomedcentral.com/1471-2261/9/15
Page 4 of 7
(page number not for citation purposes)
116 m, with a mean desaturation of 12 ± 7% at pulse oxi-
metry, despite nasal oxygen during the test (4.2 ± 3.7 L/
min of oxygen). The diffusion capacity of the lung for car-
bon monoxide was markedly decreased (49 ± 30%),
whereas the mean value of total lung capacity was 89 ±
16% of predicted, and forced expiratory volume in one
second/forced vital capacity was 65 ± 11% (table 1).
Mean mPAP (at rest in supine position and while breath-
ing room air) was 45.8 ± 10.8 mmHg (table 3), with
mPAP higher than 35 mmHg in 88% of patients. Mean
PVR was 469 ± 275 dyn.s.cm-5. Mean cardiac index was
2.2 ± 0.6 L/min/m2. Acute vasodilatator response tested
with inhaled nitric oxide was present in none.
Right-to-left shunting
According to inclusion criteria, hypoxemia was present in
all patients, with a mean PaO2 of 6.8 ± 1.3 kPa (4.5–10.0)
in room air in supine position, and 6.8 ± 1.4 kPa (4.9–
10.2) in upright position. True RL shunting was present in
all patients, with a mean Qs/Qt of 10.2 ± 4.2%. AaPO2
while breathing 100% oxygen was 32.5 ± 12.4 kPa (17.3–
62.5) in supine position, and 27.5 ± 14.4 kPa (4.5–75.5)
in upright position.
The value of AaPO2  was not significantly different
between etiologic groups of precapillary PH (Kruskal-
Wallis analysis, p > 0.05) (figure 2), although PaO2 dif-
fered significantly between etiologic groups of PH (p <
0.05), with higher PaO2 at room air in patients with PH
associated with pulmonary disease (etiologic groups 3
and 5) than in patients with chronic thromboembolic PH
(group 4) (7.3 ± 1.3 versus 6.0 ± 0.8 kPa; p < 0.05 by Bon-
ferroni's multiple comparison test). As expected, linear
regression analysis showed that AaPO2 significantly corre-
lated with Qs/Qt (r = 0.495; p < 0.05); however, no signif-
icant correlation was observed between AaPO2 (or Qs/Qt)
and hemodynamic parameters or carbon monoxide diffu-
sion capacity.
None of the patients had alveolar consolidation, dilata-
tion of pulmonary vessels, or any other lung abnormality
on chest CT that could have resulted in a RL shunting.
Transthoracic contrast echocardiography showed early or
late positive contrast in only 6/34 patients (18%), includ-
ing 4 patients (12%) with early contrast appearance dem-
onstrating intracardiac RL shunting (3 patients with
patent foramen ovale, and one patient with atrial septum
defect), and 2 patients (6%) with delayed contrast appear-
ance indicating presence of intrapulmonary RL shunting.
Patients with positive contrast echocardiography included
2 patients with idiopathic PAH, 3 patients with PH associ-
ated with chronic obstructive pulmonary disease, and 1
patient with chronic thromboembolic disease. These 6
patients were followed for a mean of 27 months. In 2
patients, PH worsened despite therapy (epoprostenol and
sildenafil; bosentan and sildenafil), AaPO2 remained ele-
vated, and contrast echocardiography was unchanged; in
three patients treated with epoprostenol and sildenafil,
epoprostenol, and diuretics alone, PH was improved or
stable, AaPO2 decreased to 10–17 mmHg, and follow-up
contrast echocardiography performed in one patient with
patent foramen ovale remained positive. One patient died
one month after initial evaluation. Percutaneous occlu-
sion of intracardiac RL shunting was not performed.
Clinical characteristics, pulmonary function tests, blood
gas analysis at room air, echocardiography, chest imaging,
and hemodynamic data were similar whatever the result
of contrast echocardiography (data not shown); AaPO2
tended to be higher in patients with positive than in those
with negative contrast echocardiography, although the
difference was not statistically significant (38.3 ± 15.7 kPa
versus 31.3 ± 11.2 kPa, respectively, Mann-Whitney U test,
p = 0.27).
Discussion
Here, we showed that, when present, true RL shunting is
related to intracardiac shunt in only a minority of
Table 2: Etiologic groups of pulmonary hypertension [1].
Etiologic group
Pulmonary arterial hypertension (group 1) 7 (21%)
Idiopathic 6 (18%)
Portal hypertension 1 (3%)
Associated with lung disease and/or hypoxemia (group 3) 16 (47%)
Chronic obstructive pulmonary disease 8 (23%)
Interstitial lung disease 3 (9%)
Combined pulmonary fibrosis and emphysema 3 (9%)
Other 2 (6%)
Thromboembolic obstruction (group 4) 9 (26%)
Miscellaneous (group 5) 2 (6%)
Data expressed are absolute values (percent of total).
Table 3: Hemodynamic characteristics at the time of diagnosis of 
pulmonary hypertension.
Hemodynamic parameters mean ± SD (range)
RAP, mmHg 8 ± 4 (2–16)
mPAP, mmHg 46 ± 11 (30–68)
PAWP, mmHg 8 ± 3 (2–14)
Cardiac index, L/min/m2 2.2 ± 0.6 (1–3.4)
SvO2, % 55.8 ± 8.5 (41–72)
PVR, dyn.s.cm-5 469 ± 275 (142–1183)
PVRI, dyn.s.cm-5/m2 819 ± 446 (262–2082)
PAWP = pulmonary arterial wedge pressure; mPAP = mean 
pulmonary arterial pressure; RAP = right atrial pressure; PVR = 
pulmonary vascular resistance; PVRI = pulmonary vascular resistance 
index; SvO2 = venous oxygen saturation.BMC Cardiovascular Disorders 2009, 9:15 http://www.biomedcentral.com/1471-2261/9/15
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patients. Hence, intracardiac RL shunting (through reo-
pening of a patent foramen ovale or atrial septal defect) was
present in only 12% of the patients, despite a shunt frac-
tion higher than physiological values (5%) and elevated
AaPO2 in all patients. This frequency is comparable to that
found in the general population [18,19], and in previous
studies in PAH (18%) [5] or in precapillary PH (26%)
[20]. Contrast echocardiography was performed by expe-
rienced operators involved in our previous studies on RL
shunting [15,21]. Although transesophageal echocardiog-
raphy was not performed, it is unlikely that important int-
racardiac shunt may have been missed by transthoracic
contrast echocardiography, which has excellent sensitivity
when the second harmonic mode is used [22,23]. Thus,
we consider that RL shunting and elevated AaPO2 were
not explained by intracardiac shunt in most patients.
Our findings are relevant for the clinical management of
patients with precapillary PH, whatever the etiologic
group. Because hypoxemia is a potent pulmonary vaso-
constrictor, and can contribute to the progression of PH,
it is recommended to maintain oxygen saturation at >
90% at all times [24]. However, hypoxemia related to RL
shunting is poorly improved by supplemental oxygen
therapy. Therefore, maintaining the adequacy of oxygena-
tion, as recommended by clinical practice guidelines [24],
may be difficult in patients with PH and true RL shunting.
In addition, our results challenge the clinical utility of
contrast echocardiography in patients with hypoxemia
related to precapillary PH.
Our study included patients with most categories of the
etiologic spectrum of precapillary PH, with no marked dif-
ferences, thus showing that our findings are not restricted
to any etiologic subgroup. Since the frequency and sever-
ity of RL shunting did not significantly differ between eti-
ologic groups, and because no known cause of shunting
other than PH was present, we consider that RL shunting
was more likely related to precapillary PH than to the
associated disease when present. It cannot be excluded
that ventilation/perfusion mismatch participated to
hypoxemia. Since Qs/Qt was greater than 5%, and AaPO2
did not correlate with cardiac output, it is unlikely that
increased AaPO2 was due to low cardiac output. Interest-
ingly, RL shunting (with increased AaPO2 and a median of
Qs/Qt of 19%) was previously reported in 8 patients with
severe PH associated with chronic obstructive pulmonary
disease (with mPAP higher than 40 mmHg, "dispropor-
tionate" to the lung disease), with no evidence of intracar-
diac shunting at contrast echocardiography [25]. PH was
moderate or severe in 88% of our cases. Whether treat-
ment of PH affects RL shunting and hypoxemia remains to
be determined, however some improvement of AaPO2
was observed with treatment of PH in few patients.
The pathophysiology of RL shunting and increased AaPO2
in our patients remains largely unknown. RL shunting was
higher than physiological shunting, which represents less
than 5% of cardiac output [26]. Transthoracic contrast
A, Measurement of AaPO2 while breathing 100% oxygen  according to the etiologic groups of patients (difference  between groups was not significant by oneway analysis of  variance) Figure 2
A, Measurement of AaPO2 while breathing 100% 
oxygen according to the etiologic groups of patients 
(difference between groups was not significant by 
oneway analysis of variance). B, PaO2 on room air 
according to the etiologic groups (difference between groups 
was significant by Kruskal Wallis analysis, with p < 0.05; two-
by-two post-hoc analysis was significant between groups 3 
and 5, and group 4 by Bonferroni's multiple comparison test, 
p < 0.05). Group 1, pulmonary arterial hypertension; group 
3, pulmonary hypertension associated with pulmonary dis-
eases; group 4, chronic thromboembolic pulmonary hyper-
tension; group 5, miscellaneous.BMC Cardiovascular Disorders 2009, 9:15 http://www.biomedcentral.com/1471-2261/9/15
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echocardiography reportedly has excellent sensitivity for
the detection of intrapulmonary shunt [27]. Experimental
studies in normal humans and dogs have shown
increased RL shunting at exertion demonstrated by ele-
vated AaPO2, positive transthoracic contrast echocardiog-
raphy, and isotope-labeled microspheres, in proportion
to the increase of cardiac output [28-30], especially under
hypoxic conditions [31], although with unclear conse-
quences on PaO2. Studies in infants [32] and adults [33]
have demonstrated intrapulmonary arteriovenous shunts,
with up to 200 μm in diameter. Large-diameter (> 25 μm)
intrapulmonary arteriovenous pathways may be recruited
with physiological exercise [30], thereby limiting the rise
in PAP despite cardiac output increase [34]. In patients
with PAH, dilated and distorted capillary circulation were
assumed to reflect collateral flow around obliterated pul-
monary arterial segments [35]. Intrapulmonary shunting
in PH may be regulated by pulmonary vascular pressure
and flow [29], and may take place at the capillary level,
the diameter of which may be higher than normal (7–11
μm) but small enough to prevent the transit of microbub-
bles (60–90 μm). RL shunting may further increase at
exercise in patients with PH [36]. Thus, RL shunting in
patients with PH might represent shunting through
intrapulmonary arteriovenous pathways recruited with
increase in microvascular pressure, similar to mechanisms
seen during physiological exercise [30,31] or hepatopul-
monary syndrome [37]. Alternatively, it might be due to
increase in complex anatomic anastomosis of bronchial
and/or pleural circulation with the pulmonary circula-
tion, as suggested in PH [38] and especially chronic
thromboembolic PH [39].
Our study had limitations, including its retrospective
design, and heterogeneity of causes of PH with potential
selection bias. Although patients with various causes of
precapillary PH were included, the distribution of causes
of PH was similar in patients with or without RL shunting
within the overall population of patients with PH in our
center, and we consider that similar results would have
been obtained had the patient population been restricted
to PAH. We could not determine whether occurrence of
RL shunting was related to more severe hemodynamic
parameters, although RL shunting was observed mostly in
patients with moderate to severe PH. The effect of exercise
on RL shunting was not evaluated. Contrast echocardiog-
raphy was not performed in normoxic patients.
Conclusion
RL shunting was not related to reopening of patent
foramen ovale in most patients with precapillary PH and
hypoxemia related to RL shunting, as opposed to classical
concepts. Our findings need confirmation by prospective
systematic evaluation of hypoxemia, shunt fraction,
AaPO2, and transthoracic and/or transesophageal
echocardiography in consecutive patients with precapil-
lary PH. Physiological studies are strongly needed to
determine the mechanism of RL shunting and hopefully
to contribute to better management of patients with PH
and hypoxemia.
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